Johnson & Johnson has agreed to buy clinical-stage biotechnology company Halda Therapeutics for $3.05 billion in cash in a deal that bolsters the healthcare giant’s oncology pipeline. Sealed Air has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback